Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Overcoming drug resistance and targeting critical pathways

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.05.12
Views: 3190

Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New York, USA

Dr Larry Norton talks to ecancer about drug resistance and targeting pathways at IMPAKT 2012 in Brussels, May 2012.


Dr Norton states that cancer research is at the point where the understanding of cancer is enough to start driving towards eradication of the disease.


While numerous pathways have been identified, there are only about ten critical pathways. Dr Norton is currently working on applying mathematics to the problem of using more than one drug in a complementary system. 


The difficulty in intelligent dosing with targeted therapy is finding a balance in treatment. If treated too intensely, resistance will develop quicker, therefore treatment needs to be slow paced in order to overcome and, in some cases, prevent resistance.


Filming Supported by Amgen

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation